Baseline patient factors impact on the clinical efficacy of benralizumab for severe asthma

Benralizumab is an anti-eosinophilic monoclonal antibody that reduces exacerbations and improves lung function for patients with severe, uncontrolled asthma with eosinophilic inflammation. We evaluated the impact of baseline factors on benralizumab efficacy for patients with severe asthma. This anal...

Descripción completa

Detalles Bibliográficos
Autores principales: Bleecker, Eugene R., Wechsler, Michael E., FitzGerald, J. Mark, Menzies-Gow, Andrew, Wu, Yanping, Hirsch, Ian, Goldman, Mitchell, Newbold, Paul, Zangrilli, James G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: European Respiratory Society 2018
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6203407/
https://www.ncbi.nlm.nih.gov/pubmed/30139780
http://dx.doi.org/10.1183/13993003.00936-2018

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6203407/
https://www.ncbi.nlm.nih.gov/pubmed/30139780
http://dx.doi.org/10.1183/13993003.00936-2018

Ejemplares similares